<SEC-DOCUMENT>0001193125-12-238366.txt : 20120517
<SEC-HEADER>0001193125-12-238366.hdr.sgml : 20120517
<ACCEPTANCE-DATETIME>20120517164100
ACCESSION NUMBER:		0001193125-12-238366
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120517
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120517
DATE AS OF CHANGE:		20120517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		12852441

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d355725d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>May&nbsp;17, 2012 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ResMed Inc.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-15317</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>98-0152841</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State of Incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9001 Spectrum Center Blvd. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>San Diego, CA 92123 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(858) 836-5000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
May&nbsp;15, 2012, our board of directors approved, subject to later declaration by the board of directors, our plan to initiate a quarterly dividend of $0.17 per share in the first quarter of its fiscal 2013, which begins on July&nbsp;1, 2012. We
plan to pay the dividend in US currency to holders of our common stock trading on the New York Stock Exchange (NYSE). Holders of Chess Depositary Instruments (CDIs) trading on the Australian Stock Exchange will receive an equivalent amount in
Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. ResMed expects the dividend will be unfranked for Australian tax purposes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May 12, 2012, we issued the press release attached as Exhibit 99.1. It is incorporated into this report by reference. The press
release describes the plan above, as well as our plans for chief executive officer succession. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
<I>Exhibits</I> </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibits:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:81pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description of Document</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated May 17, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RESMED INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May 17, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ David Pendarvis</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Pendarvis</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief administrative officer, global general counsel</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">and secretary</FONT></TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibits:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:81pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description of Document</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated May 17, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d355725dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g355725img_001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESMED INC. ANNOUNCES PLAN TO INITIATE DIVIDEND </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AND UPDATE ON CHIEF EXECUTIVE OFFICER SUCCESSION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">SAN DIEGO, California, May&nbsp;17, 2012 &#150; ResMed Inc. (NYSE: RMD) today announced plans to initiate a dividend beginning in fiscal year 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to declaration by the board of directors, ResMed plans to initiate a quarterly dividend of $0.17 per share in the first quarter of its fiscal
2013, which begins on July&nbsp;1, 2012. ResMed plans to pay the dividend in US currency to holders of its common stock trading on the New York Stock Exchange (NYSE). Holders of Chess Depositary Instruments (CDIs) trading on the Australian Stock
Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. ResMed expects the dividend will be unfranked for Australian tax purposes.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Over the past several years, we have used some of our cash to invest in our business through increased research and development, market
development, acquisitions, and capital expenditures,&#148; said Peter C. Farrell, Ph.D., ResMed&#146;s chairman and chief executive officer. &#147;We have also used some of our cash to repurchase shares. We expect to continue all these activities in
the future. Even with these investments, we have sufficient funds for strategic opportunities and to operate our business and therefore, we are initiating a dividend for our shareholders. We are confident about our future and see exciting
opportunities ahead.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, ResMed&#146;s board of directors has reaffirmed its current process for chief executive officer
succession. The board of directors has requested that Dr.&nbsp;Peter Farrell remain as chief executive officer until the end of calendar 2013, which he has agreed to do. In the meantime, potential internal chief executive officer candidates will
continue to be evaluated. When the board decides that there are suitable internal candidates for the role, the board plans to compare and contrast those candidates with potential external candidates. The process is expected to be completed by the
end of 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ResMed </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory
disorders, with a focus on sleep-disordered breathing. The Company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals
of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit <U>www.resmed.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858)&nbsp;836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612)&nbsp;8884-2090; or by visiting
the Company&#146;s multilingual Website at www.resmed.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Statements contained in this release that are not historical facts are
&#147;forward-looking&#148; statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company&#146;s future revenue, earnings or expenses, new product
development and new markets for the Company&#146;s products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and
uncertainties are discussed in the Company&#146;s Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities&nbsp;&amp; Exchange Commission. Those reports are available on the
Company&#146;s Website. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- End - </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g355725img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g355725img_001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`'`"&`P$1``(1`0,1`?_$`+X```("`P$!````````
M``````D*!@@%!PL``P$``@,!``,!````````````!P@#!08$``$)`A````4"
M`@D!!0,("`<``````@,$!08!!Q$(`!(3%!46%Q@)(3%!(AD*(R4F47&!,D(S
M0R1AH6)C-$5'.-5&)S=7*!H1``$"!`,%!04&`@8+`0````$"`Q$2!`4`(08Q
M$Q05!T%182(6@3)",Q=QD:'1(PBQ4O!B@H.3-,%RHM+B0U-C<R14-?_:``P#
M`0`"$0,1`#\`8S^H&S133+'D#=%-LIJ^0"Y=T[HP"WL5DL8=5#-)&U(2J532
M3J6IQ2#`J2"&Q10U,8,%:5U%>&/Q:&3H-IQC4VO$LUU.W46^GIW%K2X(H)4)
M$9=I"E!6?=@6]8+\_8-(%^B>6Q7./(2A2=H@8J]A`AEWX6.RJV:\\.="TR6]
M]@[_`-XWZW2^0/T:0O#]F9K$U:ISC2DM&[T(:WEX3K#$:=6.I03Z!V9@P#H'
M]6NC':HU!T,T==%6*]T5*BXH;2LA-*M>T^[$#:-I[(8!VG[?U>U/;47BUUCI
MI'%$`EQ*3EM)\P/]/MQC,R3KYWO&Q2&7(OC?J]T88Y*\#8X[)2KO,MVX:ID!
M"4UQI'WQN4J']L(5J4*4XTLE:EH!2649J"K4`L.G3+?1#J0*BVVFDI5/,MSK
M0&5M.2"`*TD@>Z5)!SVD8Y;^_P!7=$H9N5TJGA3J<EC/,F/\JA$[0#[,-X>(
MG/A)L\N2%COS=\AACT[B$FEEN;GNZ$);'%W)VA:=M<3)F0G5'42,:-V8'E*H
M5%4,J0F4[:@*A+H$(5+ZJZ&1H76R[%;%+>HG6T.-#:0ER,$=Y4($>(\<,ET\
MU6]JS2Z+Q7R(?2I25$9#RP\QCD-OX8()2^UD*TQI>.U7LI7_`+AQ&OM_,\5I
MIC38KX-M%5C^Y<_W<:SFMK.RII_\1'YXR;/=NU<B<DK+';EV_?WE;4VB-I99
MG''1S5U))&>;1,@0N1ZM1LB2Q#%J`%J@#45?2E:Z1/6FZ4[9=J*:H;9&U2FU
MI2/M)`&/VW<*%Y8;9>:6L]B5I)^X$G'UGETK;VM:>/W-GL+MVQ5'4L+U.92Q
M1-K&.@:BJ66O?ER!,:;2F&(`BJ+U]FD5)05]P<+-N8>J'P(E+:%+/A&4';V8
M]UE?06](77OLLI.R=:4QAMA$]F(Y;?,%8R\8U15H[Q6MN><@+J<O(M_/XK+E
M*$J@@@J:K3,3HN4)RJ"'2FN,-`XU]NDMPL]XM*`[=:2IIVR-KC:TB/=F!B*C
MNMMN)EH*AA]8[$.)48=^1P,SSOYF)5ED\==QY%;Z5/$)N/<*5P*U\(DL><3V
MJ0-"Q]?RGE\7LZY*,"I.J)B4=7AUP5I6E!^VF.A*Z(:;I-3]1*2GK$H<H&&W
M'W`I,R5(0GW3'+,D0CE&&,5U7O;M@T945%,J6K<4E"(&!B3'+V#"A?CTSK9X
MGW//DC9+AYGK\R&!W(OS`$:AEDEPY$X,$LC2B7G1AT2K$"E8,E>WF.20].,`
MJ:@C"JT]<-&SZBZ&T@UHJ[NT=!1MW&DI5+"VT!)3,C>)&0]X1&?W986S1NJ]
M5.ZGMB*NL=72U+J1*28'SA!CGLVX>U\@6;-@R292;RYAWD2<URB$:.0P5H4&
M`#S%<B1BHR05C`6+$1Q:A^5EFJ*!I6H$9)P\,`5T1S0>E:G6.JZ/3M-L>=3O
M%&/E;!)43#.`]T>)&&QU??VM-:>JKN]"*4$(B816<@!X[5?8,<ZMASJ>2.:7
M"@L#[M<R":5W9D$-0LB8JY<G2"&;<MV0)F-6D;TZPL"-,L`[EGIRPAI0)`P5
MI35K33Z%U&B^GEKMK]Q9MM$JEIV5CS-I/RT>:)/Q!22#XX3=G6&N*N_,4BZY
M]&^>00D$P@X8IR\1#V$8Z:)$O@EJV.*P^;W*C+8Z-D;:4!:N:R]G:WI\*:T9
M+88]'\:7IE:\Q:H2B$:?@+7.J+&NMCI\UTL5]VJ'JNBI75-K>696T%01,HD(
M\HAD-GA##Q"HIZ-M%/5O-AU+:02I205$#,P)[=N/==K(_P#F*U?O_P!0XC_Q
MC2<V*^@P-#61_P#"O\L>N:6O_P"FG_Q$_GB24N'!!1P4P!,XF9$0"J`<K!)&
M:L:`,*D*.H!OU%O"@#HL%0K"IN.TKJ_K>FG&JCK4U0H2P]QQV-R*GV1]V$=F
M>)A5,%@U25MFF!]Z=,OWQAB-TOK9.OLO#:RM:4K6M*7#B%<*4]M:_?'LIIU<
MCO\`\-OK3_=+_+$/-+9#.IIQ'_N)_/$VI*HS5DK)N86/EJA&]5D7%D'`MVUZ
M%[QQ?>.'[#:"H'7VFKC7#''3CX6LXC@]R[QLT-W*9XPC"6$8^&.@5%.6#4AQ
MOAQ\4PE^^,,)J?597C+63K*38!.=07`(W/KQ/B8!F-:'R)P;87%Q'`"+6"(!
M#`ZU!6M*>AE?RZ-Y^UJRI#-UO92M;CCC;*)8C8)U$$`Q`)$<O;A:/W#W$J-!
M:TGR@*<4(B(CEVCPQ%_'U]01E9R3Y/[)Y:E^7V]TB?+;Q]Q)E,D8EMN4S,_R
MN02!WDS^Z-Q:^1)5PDAS@[#H5MBP&[,`:"IC33HUU^W_`%;J_6%=J%-=1MM/
MN`H0X7)@D)``C(!'+O\`LQ'I#K%IK3.G*6T)I:HNM),T(0))))^S/%:?(%Y(
M;G>;V?6%RBY:;*&0)G!.%$C8V>X$_BB%\G,[/:%C.A6N[F:I01IA88TQKU0R
MTA)RY<K-/$(%!C"`JNBT)T\MW0ZBN.KM25JJMQ3$BDM-F1""02@>\HDJ2"%0
M``3`C..,_K'7=9U8J*32^GZ;=4X="C.H3%68\!D"<L]I\,&;S96-;/%'X!+F
MV`2R4I_G,P94L#E$I0%C1II/<Z^TM0$3L]J).H!11H01@2M(BH90)HD*$`AT
MH*M0T"VEKK5=4NN5-=DI4FD#D[:"1,AIA)E!5"&9@=F2B81C@K:@H6^GO25Z
MVL_YH("%*!E\SJA,1M/E3'[0(Y8#7D`\2OCMS&96;>WDS)YYF.R=TIHIE"M9
M;5!=*P\:,CC"@DSFRQWB;-,TZB0(G-S;FP*L83A4IJ'AU0T#A6IIUWU6Z@V+
M5%5;;#8GJVU,%*4NJ8J3$E`48*1*D@;/83D,"_1W3O1=ZT[3W"\W93-R=*ID
MA]L;%%,(+^_V]N#F>/'Q"Y"LJ=Y#LWV73,[(,Q[K:.+S5I.0H)7:6:1QE5R.
M,G%+3%*RWS0!2CD'`*G43%#/#K`45%4-:5I70&=1^JNL]5V@:1U#:D6U%4IM
M044/H6I,WP[U1R/>!]^"QHWIUI/3M>K4-GKW:PTZ51&\0X@&4[9`,X$Y'`$L
ML5<OOF1SEWONGY*LV9MI&@L]"99.T1D[9X(C7,3JO=TR&(PV0S,APCL>:(0U
M-Z2BQ.F++<G1<M$H&+]YB>=3IO72/15MM_36U"LJ%,A514AG>J2J"2"0F!5,
M2K,D@`0[A@36%=FZD:JK:[6=<6&VW`EIHKD"@21`3;``!^';$XOC,_!!??+?
MG!R_9A?%E,PRRU4>>(C+'Q^G-W(JD>F-0@E"<N41E,[,R%`"=0V30^@ML2,J
MNM4P90JCI4%0X"DZY6+46EZ^P]3J="+@XA24%#"B5K*3*HQ/Z90K(`$QCV0Q
ML7>D]PL>H:6\Z&J%KH`N+B2XG(1&0,0""-IA&$?;F_JN+R%`091;!)E--8U?
M<*]$A3T,$$-$C<F0PF+&F@IAAKFN3MJ5K[:EUPTE_:C:DKJ+I>7H2*"*9((S
MS45J(/\`J@98A_<-<2BDH+4W&9Q:EY?S)@D1'WP[L\#23VF%E^SY>#>#J"-V
M=ZVBR>SB0@`52AE'^Z5\)Y/'(!P*>TU/S(`D=:_%2A?K[--]3W5>HM$ZVKE+
MF:-75H0K^HQ3I`'V`(_'&05:D6;5NEJ4P1&G8<(A\2W"K[R3#!4/-W-Y!G[S
M]Y4O$_:=S/JUM$I:II>]S;A&'$,KK(FPU<H5KZ%"&1_TTM&6N=*Z]*?S+L47
MZ#I2F@RZ,4C.A]#W;JE<D_JJ94U3).15!02F4GM<=(`RRD[E9;CJC4NZKU=;
MM!4!BVA>]>/8#M@>Z5N),<B%'M&!/9"(?'LU'G9B2B(MQ1=LX/?>:SF.(:`"
M)(WVPR[-;@U6U3;,-*D!("FBS&33"E*5$.F'MT*NNZMW3W0YPU*U*N#]*VA9
M)@HO52@MS[IU*/@,#W2-&U>>KX#21P5.ZHI$(B1I,$?@D".+&>6-NM]G?\Z<
M6R]7(N0U6WM+`H_!+1S.XSJ]QU@0PYK;XJ[W4FZTEYE@^74#H8OD`$)-%&L$
M:K4#4(JX4TS_`$N-3HSHF]J.DI%U5U>6XZVV`M4ZIPA!E;\P@D1)[1B^Z@BG
MU1U418:FHX>V-A`<5O$H@)8F!)`CM$.\#OQ9PCP1>'I:I3IDGDR+4*E9R=&D
M2);TY83E*E4H-`G2IDZ<AL$8>H4G#"```AJ(8A4I3&M=,V[UPZK-A2ZG3("4
MHF4M5/5!,.\DJR[XG+QQ=IZ0].77=TQ>W%+*H`"H8)B>P1$3C8OFVM[;SQZ^
M'BPV1>VCR\NS')[N-[24Z2`+:!^DC'%G&2W=ECJ]E-2-"WFGGRA4W`%0LD(`
MAJ"FKZ:5?1VOJ]?=7JO6]>EMAUFFWDB$DH2J5ME"1.21$`G..<>S';U.I:?1
MG35C3-M6M8<J9`M2A.0I2UJ42F`(BH#LRAB,9;_IC,N]V\L=E[EW"O3>Z(73
MN7::'S>0-3(FM^IB\<D$P84;Z!$G:U\5XJI0M@7`LLPHQ<$TRH!?:`Q].G4O
M[DK]0:DJZ&DH:)=NIZEQN*IPI80J4S*2H)!)!(@F$(98ALO0^SUMEIZVIJZQ
M-P?80LP*2E!4D*R21$@>*H]T,!BL3';YQJ79VO$>&X]'.$W-GUM+,GF+E;FI
MAL:F\'SMV&B:*YS`R&K!A:N*LKBH"N2$C!O5!$@,'4901Z%6^O6=RALG5K@F
M45K3#[\@&3B56^I<E48S$I@"%1C$`X&EH;NJ*J[=..)<50K>91.=J2FL83,!
MLSV$=QAW8VSY?'59G$\US_:&/'J%H"[CV-RML998Q'4*-*JP(931.&GH66DD
MDH<QF!IA^['6OY=.3I13,Z2Z)<T>44.KIJBH*HE!CG)FD@^Z`1^6.KJ,XK4G
M5=-M2@+80\TS#W@80F)$1L5$$?CAWFGCDR$@0DM]<FV6A02!*4BJ8?9:`FJ#
M2RB0D4,.4U8ZGF&C"#$0ZBJ.HO6M<?71-%]1M?.E2TWBXI.:@=^LB,3E`F']
M,L-&WHK2;*$M<OH]V`!DTD$[!MV_?'"!UXK10E3YK'*Q^6)E(AD-0YY(!![?
ML<>$:2VQ96P3>*%283`(`QF(&YJD#>XGD!`*H""@:H<`!I2CRVVY.KZ(JNFH
MG-[4+LRW'%+$Q<4I)D!SR)RBKM,3A1Z^UTC?5T6W3Z`T@5Z0F0D2YP5V[$]W
M@,\'S^JMN^8EM1E6R]M*C;.DYN++;FN#8`>%34T)9"8E&]L"E::P5;U.3MGK
M84UT]:_LZ`W]L-K2J[W>_+25)8H@VF!@9EG>9';_`,N&6>9P6^OER*K7061I
M2AOZ@K7#M2W!&<>R*R?M&))!OIQ_&JOA,-6SR_\`=,$Y5Q..*9H6T7CM00U`
ME9S,D,D(&Q.?"E9Q#<%V&=0D`S31!*H&E1BK36KY6_N&ZEHJ7FJ>WT_#A:@@
MJ8J%&4$@9EV!,-IE!_AB>W='M`FA9W]2\7BVDF5]M.9`)$"##!%[;1#([X-,
MEEQIE&'RX<ULJ9=1K?9F_H3(U<R<KI9-N6H0UMU11\F,-9K6WEIDM*%F:@B"
MS!B$(6OAH,[M6Z[ZS:S98=0PW>%,A#;<JFD(0B))BM2B-N-U0TVE>F6G'ZJE
MWRK3/,M14ATDGR[4A(AXGOP.U!X=_%CY6[<]V^4Z2W-R]([@NTD,=&2.@C9S
M"T2="]N*5[YDM*_&O08BO5+BA*:)$3DA3C3&EF%E@".E="`>K74_I;6#2FHF
MV*Y-.$RS`DE)_P"FZ(1[`24JV=IQBU].NG_4&D%_LRG*5QTJ)4V4P!\4QR[=
MB@#@7/CUA=Z\D7FPA&3BP68A3>VW"*:*F2ZAD&7.1-M9'`:096_RP4GB(75Y
MC[?)[?&B**..)--JD="0%`.IKB*T*&O*RRZUZ,/ZROU"W17-+1+4R4EQ"RX$
MH"5!*%%+I`B2,DG,;<8#1=+=M,=3D::M=<JJM87!PI)(("28+$2`1F-IS$<1
M7S9.J_-SYGFJP<?4&.1#,ZV`RSM28L6T*)<9&N0/<JH6&E:A#5*X3L^AM*4]
MJ>N/K32PZ.LHTOT4=O54E+54ZFHJ9_`(*6S_`+)`Q#U/=&H>J5-9&B5M-+:;
MR^`DB?+MS.>>+"><Z:QS+AY><F-R36T\R*V,M5EYE]6=M``*E8R6ZNQ,7`MH
M2^M`A$<A::)P^ZE!_P!&F7Z&T57J7I??;:A4*BMJ*A`/<IZG0DF']K\,6?5>
MH9LO4*TU2U?H4S#2MD():6I0']HCV>.)KXOT4I9K!>4+S8WOH(4WF</O<UVE
M<%H:5-+>',*QPE#NR*#M8PA'S>K9HV@&#"E"6X\JGP^FG#U)>IW;YIGHQ8_\
MJPNGX@#M*<H$;"?>48GM![,6NAVZ@VF]]3[B@\:^EP,D]B5?$D[89@`0[".W
M$3^E=M+5SOOF;S!O10!(+:VFC\`(=U>-0$O5PGT4D?5&V-#C0TEF@U*FB]*U
M`?Z^E=+3]TUSX>T6W3%'\]ZJ4XH#N;;2VG+[5"`/:/#%9T!H4O7:X7QWY;;<
M$J/]=1)S\`#'[<5LR-94;+^7K/[GHN-F,GDAAMKAR:87';'.,RN/1=W='V:W
M*<4,':P+I2W/"4YM0PIH.&,HHBHJ:A.(@TPI6]UKJZ]=*=`V"V:;8W]4&4H=
M0M"U@2MB,9"DQ),?>_ABLTSIJT]0]8W:X7QYQNG0ZI2)%(3-%4(3*!/X0P=&
MV?T]/B^@%R;?3QDO3=&1/<(F\3ES(P/5V[6N30\O$9?$#TTMCHW(H4E6+T"Q
MP1%@-(),+,-!6H0BI6M*Z!2OZ]]2:JTU%M>HJ9NE?IU-N+2P^#*H$$S*=5`@
M=^0P4[?TFT'15C+]/55!K&WDJ2-^T22($`IDS]F9&*"_45OH\PGD%R,9-6MP
M3C"G0Q^KV6H4@3I&YUOK<MM8#%"T9IA9*<*.)P_>!#&(-`$FXUKA73=_M^HU
M63IW?-95")FU*6A,D5*_294I,.W-:HP`VI@,9'K(YS?6EFTZ@J\J@5QA"#BP
M!'8/*$@^(/MPSCF9SJ99<D]AWNXT\N+"T3+"8W5##8<U2-G5R6:.[4V[O'H7
M$V)$H-6KG!Q.3E$8EE5)2EBJ::(!0!"HM%ATCJ?5]]1;J2DJ5NONS+<*#*`2
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MY)UCZX[CUIX%OB?;\K\._"W3GC.SV_+_`-GO&SW[[79:*)U_^I_,&_5&[])3
MJW/#0X;W<H_%&,(3>S*.&.Z1>@^#7Z?GYW*-]OOG1S]FS;#.&W+`OK&]G'S[
M?QOW3=?^\R[&//'1WI1U+UYIR[K<&_%O`=MN_!?X^MNFT]^A6O7J?Z#GAN6\
MAY:S#=[_`'N[B([?)&,TW9M\,8:V^G/J\=]QG.>*7[^[W<<X>,([.V,/'$T^
MHM[0>]Z#]=NY[G/MUB.X]&^E'+'`^<[@;EM^>OO3C6^;?::OV&SV>'KKZ5W[
M<_5GI.L]/<!N>-3\_?3SRI]W=^6$(1CGCSK5Z:]3,<[XO?<*GY>[EEG7MFSC
M';X;.W!(,T_;!_\`/A#.FG5OM-Z7V)WWI?R7U0Y=YXCO,?,?,WX;XMU#UN9-
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MRVN^W*-P[N_XUUZM_P`M]1NA/(W-7%@<J\T<N??'">8MUU]W^/6U?=CI@>H?
MK3T1=8\FX;@US[G?;R$3-)/E-",(Y;,:W0WHSU?1<#S'B-^F&]W<L8B$W;#_
M`$;,6@\W':)\RJ^O7_O(Y^X7;'8].NBG(_*_3IBY>Y9YG^_]SU-MMMM\6^[?
M#X<-*7HCZE^FE'R#E7*]XK>[_B)Y]XN.]E\D8=WPPQ>]4/37K2HYKS/FL6]W
MNMW+"1'RXYPV;?BC#%/\HOR2NLS'W+]Z/)>NGW?GOD7D+>]NFUN<>D7X[Y<V
M/^(W3[/4PU_AQTTVJ_K#R-?I7D_$2JCP\V^ES^5O,MFR&,_IOZ<\S;]0<RX>
M?R\1"2:;*:7/WMO;MQT#_P#U'[3O]%NS#I1[^6.B'2+AWN_Y?Y<W''^UM?[[
M1#%>L/5B9>,]9\29O>XC?1RC\48]WP_U<-R/3W(S'A_3&Y$/=W,O\/\`B\<?
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
